Antimicrobial Chemotherapy Conference 2019 – An ABC for Everyone Involved in Developing New Antimicrobials

15 January 2019, London

Organized by the British Society for Antimicrobial Chemotherapy (BSAC) in collaboration with GARDP

Session 1: Antimicrobial drug discovery – an essential overview

  1. Opening Remarks
    • Laura Piddock, Head of Scientific Affairs, Global Antibiotic R&D Partnership (GARDP)
  2. The risks of clinical development from the perspective of the antibacterial discovery scientist
    • David Shlaes, Former Professor of Medicine, Case Western Reserve University, Ohio, USA
  3. Overview of new antibiotics in development
    • David Livermore, Professor of Medical Microbiology, University of East Anglia
  4. Overview of new antifungals in development
    • David Denning, Professor of Infectious Diseases in Global Health, University of Manchester

Session 2: Things we forget that come back to bite us!

  1. Things clinicians don’t often consider (CMC, GLP toxicology, Phase I studies)
    • Lauren Walker, Clinical Lecturer at Royal Liverpool University Hospital
  2. PK-PD programs for drug development
    • George Drusano, University of Florida and an Institute Director (Institute for Therapeutic Innovation)
  3. Invited paper – Identifying carbapenem and amikacin-sparing first-line combination therapy for neonatal sepsis in high extended-spectrum beta-lactamase (ESBL) prevalence settings
    • Joe Standing, Principal Research Associate (MRC fellow), UCL Great Ormond Street Institute of Child Health
  4. Invited paper – Light controlled release of antimicrobial peptides for the treatment of pathogenic bacteria
    • Samuel Moorcroft, PhD Student, University of Leeds

Session 3: Tackling Beta-lactamase mediated resistance

  1. Beta-lactamase inhibition: A potted history of beta lactamase and lessons from recent development of beta-lactamase inhibiter combinations
    • Shampa Das, Senior Lecturer, Molecular and Clinical Pharmacology, University of Liverpool
  2. Metallobetalactamases and development of new compounds
    • Martin Everett, Chief Scientific Officer, Antabio
  3. Invited paper – REVIVE – a programme to support and connect the antimicrobial R&D community
    • Astrid Pentz-Murr, Community manager REVIVE, GARDP

Session 4: The Way Forward: Clinical Trial Design and New Drug Development

  1. Stimulating Antibiotic R&D through links to sustainable use and novel economic incentives
    • Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents
  2. Developing a new drug for STIs
    • Emilie Alirol, Project Leader, Sexually Transmitted Infections, Global Antibiotic R&D Partnership (GARDP)
  3. Innovative clinical trial design for unmet clinical needs: neonatal sepsis
    • Julia Bielicki, Consultant in Paediatric Infectious Diseases, Lead Physician Infection Prevention and Control University of Basel Children’s Hospital
  4. Clinical Trial Design for new antimicrobials: adults
    • Aaron Dane, Director, DaneStat Consulting Limited